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Background and aims: Coronary artery disease (CAD) risk is associated with non-coding genetic variants
at the phosphatase and actin regulating protein 1(PHACTR1) gene locus. The PHACTR1 gene encodes an
actin-binding protein with phosphatase regulating activity. The mechanism whereby PHACTR1 in-
fluences CAD risk is unknown. We hypothesized that PHACTR1 would be expressed in human cell types
relevant to CAD and regulated by atherogenic or genetic factors.
Methods and results: Using immunohistochemistry, we demonstrate that PHACTR1 protein is expressed
strongly in human atherosclerotic plaque macrophages, lipid-laden foam cells, adventitial lymphocytes
and endothelial cells. Using a combination of genomic analysis and molecular techniques, we demon-
strate that PHACTR1 is expressed as multiple previously uncharacterized transcripts in macrophages,
foam cells, lymphocytes and endothelial cells. Immunoblotting confirmed a total absence of PHACTR1 in
vascular smooth muscle cells. Real-time quantitative PCR showed that PHACTR1 is regulated by
atherogenic and inflammatory stimuli. In aortic endothelial cells, oxLDL and TNF-alpha both upregulated
an intermediate length transcript. A short transcript expressed only in immune cells was upregulated in
macrophages by oxidized low-density lipoprotein, and oxidized phospholipids but suppressed by lipo-
polysaccharide or TNF-alpha. In primary human macrophages, we identified a novel expression quan-
titative trait locus (eQTL) specific for this short transcript, whereby the risk allele at CAD risk SNP
rs9349379 is associated with reduced PHACTR1 expression, similar to the effect of an inflammatory
stimulus.
Conclusions: Our data demonstrate that PHACTR1 is a key atherosclerosis candidate gene since it is
regulated by atherogenic stimuli in macrophages and endothelial cells and we identify an effect of the
genetic risk variant on PHACTR1 expression in macrophages that is similar to that of an inflammatory
stimulus.
© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/4.0/).1. Introduction
Coronary artery disease (CAD) is caused by atherosclerosis, aS, genome wide association
TR1, phosphatase and actin
PP1, protein phosphatase 1;
ription start site; RACE, rapid
dothelial cells; LPS, lipopoly-
inobenzidine.
.A. O’Callaghan).
r Ireland Ltd. This is an open accesform of chronic inflammation. Deposition of pro-inflammatory li-
poproteins in arterial walls is associated with the development of
atherosclerotic plaques that can obstruct blood flow and trigger the
formation of occlusive thrombi [1,2]. CAD is a complex disease with
a strong heritable component [3]. Genome-wide association
studies (GWAS) have identified 58 genomic regions where single
nucleotide polymorphisms (SNPs) are associated with CAD risk
[4,5]. Most of these disease-associated variants are in non-coding
DNA and likely exert their effect predominantly by altering tran-
scription factor binding to regulatory DNA elements [4,6e8]. A
number of CAD risk loci contain genes that were not previously
implicated in coronary artery disease and for which no mechanisms article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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ported genetic variant. Understanding the effect of these genetic
risk variants on the expression and function of the genes that they
regulate will advance our understanding of atherosclerosis and
could lead to new therapeutic targets.
Several studies have independently replicated an association
between CAD and SNPs at a genetic locus containing the phos-
phatase and actin regulator 1 (PHACTR1) gene [9e12]. SNPs at the
PHACTR1 locus are associated with the specific phenotypes of early
onset myocardial infarction, coronary artery calcification [11,12]
and with an intermediate phenotype of impaired central hemo-
dynamic indices, indicating abnormal vascular stiffness [13]. The
PHACTR1 locus is pleiotropic since the protective alleles of the CAD
risk SNPs are associated with an increased risk of ischemic stroke
caused by cervical artery dissection, a form of non-atherosclerotic
vascular disease [14]. The variants reported in these studies lie in
an intronic region of PHACTR1 over 250 kb away from any other
gene. A genetic fine mapping study suggested that rs9349379 was
the most likely causative variant at the locus and it was associated
with expression of PHACTR1 mRNA in composite right coronary
artery tissue [15]. An expression quantitative trait locus (eQTL)
study assaying gene expression in diverse human tissues showed
that rs9349379 also affected PHACTR1 mRNA expression in aortic
artery and tibial artery tissue [16]. In a whole genome epigenetic
and expression study, we recently demonstrated that PHACTR1 is
one of the most highly upregulated genes in macrophages exposed
to oxLDL [17].
The PHACTR family consists of 4 genes encoding proteins that
interact directly with both actin and protein phosphatase 1 (PP1)
[18]. PHACTR1 was originally cloned from a rat brain cDNA library
using a yeast two-hybrid system with PP1 as bait [18]. The human
PHACTR1 gene is on chromosome 6 and a transcript with a 1743 bp
open reading frame has been cloned from human brain [19]. The
resulting 580 amino acid protein has 4 highly conserved actin-
binding RPEL domains and both mouse and rat orthologues have
been shown to bind actin [18,20]. Human PHACTR1 protein con-
tains nuclear localization signal (NLS) motifs at both ends of the
protein that, in the mouse ortholog, have been shown to facilitate
importin-dependent nuclear translocation in response to serum
stimulation [20]. Binding of the RPEL domains to G-actin maintains
PHACTR1 in a cytoplasmic location [20]. Serum induces Rho-
dependent remodeling of actin from G- to F-actin and trans-
location of PHACTR1 into the nucleus [20].
PP1 is part of a family of serine/threonine phosphatases that are
present in both the nucleus and cytoplasm [21]. The enzymatic
specificity of PP1 enzymes is achieved in part by their association
with accessory proteins [22]. PHACTR1 may function as an acces-
sory protein since PHACTR1 binds to PP1 and inhibits its activity
in vitro [18]. PHACTR1 may also affect actin structure as siRNA-
mediated PHACTR1 knockdown in human umbilical vein endo-
thelial cells (HUVEC) reduces F-actin filament numbers and repar-
titioning as well as increasing cell protrusion dynamics [23].
Although the precise cellular role of PHACTR1 remains to be
determined, overexpression and siRNA-mediated knockdown ex-
periments suggest a role in cell motility and vascular morphogen-
esis [20,23,24].
Atherosclerosis involves the interplay of genetic factors with
atherogenic stimuli, such as modified low-density lipoprotein, in
cell types including macrophages, lymphocytes, endothelial cells
and vascular smoothmuscle cells [1,25e27]. The role of PHACTR1 in
these cells and the mechanism whereby it alters CAD risk are un-
known. Understanding the role of PHACTR1 is complicated by the
fact that the human PHACTR1 gene is predicted to encode multiple
transcripts that have not been characterized. In this study, we hy-
pothesized that PHACTR1 is regulated by atherogenic orinflammatory stimuli and that its expression is influenced by CAD-
associated genetic variants. After establishing the expression of
PHACTR1 protein in atherosclerotic lesions and the profile of hu-
man PHACTR1 transcripts in primary cell types involved in
atherosclerosis, we determined the responses of these transcripts
to inflammatory stimuli and to atherogenic lipid. The role of
PHACTR1 in CAD was highlighted by its in vivo abundance in
macrophages and foam cells in human atherosclerotic plaque. The
CAD risk allele at SNP rs9349379 was associated with significantly
reduced expression of a short transcript in macrophages such that
the risk genotype mirrors the effect of an inflammatory stimulus.
2. Materials and methods
2.1. Ethical approval
Ethical approval for the study was obtained from the NHS
Research Ethics Committee (South Central-Hampshire B, reference
13/SC/0392) and all participants provided written informed
consent.
2.2. Cell isolation, culture and reagents
Primary human coronary artery vascular smooth muscle cells
(Invitrogen, Carlsbad, CA) were cultured in Medium 231 (Invi-
trogen) and Smooth Muscle Growth Supplement (Invitrogen). Pri-
mary human aortic endothelial cells (Invitrogen) were cultured in
Medium 200 (Invitrogen) with Low Serum Growth Supplement.
CD14þ monocytes, T cells (CD3þ) and B cells (CD19þ) were isolated
from the peripheral blood of healthy human volunteers. Blood was
centrifuged over Ficoll-Paque PLUS (GE Healthcare LifeSciences,
Buckinghamshire, UK) to isolate peripheral blood mononuclear
cells (PBMCs). Subsets of cells were isolated using positive selection
with magnetic bead-conjugated antibodies (Miltenyi Biotec, Ber-
gisch Gladback, Germany). Individual populations were confirmed
to be >95% pure using flow cytometry for the markers used for
positive selection. The cells remaining after CD14þ cells were
magnetically separated from PBMCs were termed CD14þ-depleted
PBMCs and constitute a mixed predominantly lymphocytic popu-
lation. CD14þ monocytes were differentiated into macrophages by
7 days of culture in RPMI 1640 medium with 10% fetal calf serum,
4 mM L-glutamine, 50 units/ml penicillin and 50 mcg/ml strepto-
mycin (Sigma, St Louis, MO), supplemented with 50 ng/ml macro-
phage colony stimulating factor (M-CSF, eBioscience, San Diego,
CA). Foam cells were generated by treating macrophages with
human oxLDL (50 mcg/ml) for 48 h. Foam cell formation was
confirmed by oil red O staining for intracellular neutral lipid by
light microscopy. Macrophage and foam cell viability was shown to
be >98% using the Invitrogen LIVE/DEAD microscopy kit.
Ultracentrifugation of freshly isolated human plasma using a
discontinuous potassium bromide gradient was used to purify LDL
with density 1.019e1.063 g/ml [28]. LDL was extensively dialyzed
against PBS, and incubated with 25 mM CuCl2 at 37 for 18 h to
produce oxidized-LDL. To terminate oxidation 1 mM EDTA was
added and oxLDL was stored at 4. The TBARS assay was used to
confirm that LDL was oxidized (Caymen Chemical, Ann Arbor,
Michigan). Careful precautions were taken to ensure low endotoxin
levels and LDL was tested for endotoxin using the gel clot method
after heating to 75 for 15 min to remove the plasma inhibitor
(Associates of Cape Cod, East Falmouth, MA). LDL was used at levels
of <0.1 EU/ml.
2.3. Genotyping of rs9349379
Individuals providing blood samples were genotyped by the
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an inventoried Taqman genotyping assay according to the manu-
facturer’s instructions (Applied Biosystems, Foster City, CA, ID
4351379).2.4. RNA extraction and cDNA synthesis and 50 RACE
RNAwas extracted using the Trizol RNA Plus extraction kit with
on-column DNAse treatment according to the manufacturer’s in-
structions (Invitrogen). cDNA was produced by reverse transcrip-
tion of 1 mcg of RNA using Bioscript reverse transcriptase (Bioline,
London, UK) with random hexamers (Qiagen, Venlow, Limburg,
Netherlands). For 50 RACE, 5 mcg of total RNA was reverse tran-
scribed using 20 pmol of gene specific primer (CO5441
TTTGGCTGAAGGATCTTGGG) and then poly A tailed at the 30 cDNA
end. First round PCR was performed using an inner gene specific
primer (CO5439 CCATCCATGATGTCTGACGGTTGG) and oligo(dT)
primer (with additional 50 sequence for round two PCR, CO1352) for
18 cycles using Bioscript (Bioline). Second round PCR was per-
formed using gene specific primer (CO5400
CTTCTCTGCTTTGCCTCATAGATATTT) and a primer (CO3984 CTAG-
GAATTCTAGAGGTACCTCGAG) annealing to a 50 prime site created in
the 1st round PCR. PCR products were gel extracted and ligated into
Strataclone vector pSC-A-amp/kan using the strataclone PCR
cloning kit (Agilent, Santa Clara, CA). Colonies were cultured,
plasmid DNA extracted using a miniprep kit and sequenced using
BigDye (Invitrogen) with both inner gene-specific primer (CO5513
CTGACGTGTGTTTGAACTTTTCGC) and also (CO5400
CTTCTCTGCTTTGCCTCATAGATATTT). Sequences were aligned to the
hg19 reference genome using the BLAT program in the UCSC
genome browser.2.5. PHACTR1 cloning
The long PHACTR1 transcript was amplified from an Image clone
(IRATp970E05120D) using primers CO4400 ACTGATGATCAATG-
GATTATCCCAAAATGGATTATTTTC, and CO4807 TCAGTCTCGAGT-
TAAGGTCGGTGAAACCTTGTTAAGTG and cloned into pCDNA3.1
with an N-terminal myc tag to produce plasmid pOC1259. The in-
termediate transcript was amplified from CD14þmacrophage cDNA
using primers CO4976 ACTGATGATCAATGCGTTCTGACTCCCTCGTCC
and CO4807 and cloned into pCDNA3.1 with an N-terminal myc tag
to produce plasmid pOC1256. The short PHACTR1 transcript
(ENST00000379335) was amplified from macrophage cDNA using
CO4806 AATGAGGATCCATGTATCTGCAAGGGCCGAGG and CO4807
and cloned into pCDNA3.1 with an N-terminal Myc tag to make
plasmid pOC1257. Plasmids were sequenced using BigDye.2.6. Tissue bank and primary cell expression analysis
An oligo(dT)-primed cDNA library set made from adult and fetal
human tissue was screened for expression of PHACTR1 transcripts.
PHACTR1 transcripts and beta-actin controls were amplified using
BioTaq polymerase with 33 cycles and 25 cycles respectively.
Products were run on a 1% agarose gel and stained using ethidium
bromide. The primer pairs used were as follows: long transcript,
CO3948 TGCTCACAGACTCTTGGATGTTG and CO3880
CTTCTCTGCTTTGCCTCATAGATATTT; intermediate transcript,
CO3879 GGAAGAAGAAAAGCGAAAAGTTCA and CO3876 GGCAG-
TAGCAGGACTGGTTTG; short transcript, CO4987 ATGTATCTG-
CAAGGGCCGAG and CO3944 TGAATTCATTGAGCTCCTTTCG; control
beta-actin, CO1851 TCCAGCCTTCCTTCCTGGGCAT and CO1852
GTCAAGAAAGGGTGTAACGCAACT.2.7. Quantitative PCR and eQTL analysis
Expression levels of PHACTR1 were determined by RT-qPCR with
SYBR green reagents (Invitrogen) using either cDNA frommacrophages
or CD14þ-depleted PBMCs from genotyped healthy individuals from
the Oxford Biobank. RT-qPCR primers used were: CO5399 GGAAGAA-
GAAAAGCGAAAAGTTCA and CO5400 CTTCTCTGCTTTGCCTCATAGA-
TATTT (intermediate transcripts); CO4987 ATGTATCTGCAAGGGCCGAG
and CO5122 CTCTTGATCTCTCTCTTCTCCTCCTG (short transcript);
CO3744 TTGCCATCAATGACCCCTTCA and CO3745 CGCCCCACTT-
GATTTTGGA (control GAPDH). Melt curve analysis demonstrated a
single product for each primer pair. For each sample, triplicates were
assayed. A Kruskal-Wallis test was applied across the three possible
genotypes to identify a significant genotype-expression relationship
with significance defined as a p value < 0.05. To assess PHACTR1
expression in response to stimuli, primary human macrophages
(rs9349379 AA) were treated with 50mcg/ml oxLDL for 48 h,10 ng/ml
LPS (Sigma) for 24 h, 10 ng/ml TNFa for 24 h (eBioscience), 30 mcg/ml
OxPAPC (Invivogen, San Diego, CA) for 48 h, or 10 mg/ml cyclodextrin-
cholesterol (Sigma) for 48 h and assayed in biological triplicates. HAEC
(rs9349379 AG) were treated similarly with 50 mg/ml oxLDL for 48 h,
10 ng/ml TNFa or 10 mg/ml cyclodextrin-cholesterol for 48 h. Coronary
artery smoothmuscle cells (rs9349379 AG)were treatedwith 10 mg/ml
cyclodextrin-cholesterol for 48 h and assayed in triplicate. Student’s t-
test was applied with significance defined as a p value < 0.05.
2.8. Western blotting
Cells were lyzed in RIPA buffer with protease inhibitors and
subjected to SDS-PAGE analysis using 10 mcg of protein per lane
and PageRuler Plus pre-stained marker lane. Endogenous PHACTR1
was detected using a rabbit polyclonal anti-PHACTR1 antibody
(Novus Biologicals, Littleton, CO) and secondary HRP-conjugated
goat anti-rabbit IgG antibody (Vector labs, Burlingame, CA).
Chemiluminescent reactions were performed using ECL Advance
(GE Healthcare LifeSciences) and imaged using either a BioRAD gel
doc imaging station (BioRad, Hercules, CA) or Amersham hyperfilm
ECL (GE Healthcare LifeSciences).
2.9. Immunohistochemistry
Formalin-fixed paraffin-embedded tissue samples of non-
atherosclerotic aorta (n ¼ 5), and atherosclerotic aorta (n ¼ 5),
obtained with full ethical approval from the National Research and
Ethics Service (Oxfordshire Research and Ethics Committee A:
reference 04/Q1604/21), were immunostained for PHACTR1 with a
rabbit polyclonal anti-PHACTR1 antibody (Abcam, Cambridge, UK)
detected with the NovolinkTM max polymer detection system
(Leica Microsystems, Buffalo Grove, IL), as per the manufacturer’s
instructions, or with detection reagents only, as a negative control.
Slides were mounted in Aquatex mounting medium (Merck, White
House Station, NJ). Stained sections were photographed with a
Nikon DS-FI1 camera with a Nikon DS-L2 control unit (Nikon,
Tokyo, Japan) and an Olympus BX40 microscope (Olympus, Tokyo,
Japan). All immunohistochemical staining was analyzed by and
performed under the supervision of an experienced board certified
consultant pathologist (EJS).
3. Results
3.1. PHACTR1 expression is increased in human atherosclerotic
lesions
To investigate the role of PHACTR1 in CAD, we used immuno-
histochemistry to evaluate human PHACTR1 protein expression
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atherosclerosis (n¼ 5) and in normal arteries from healthy controls
(n ¼ 5). In healthy arteries, PHACTR1 was expressed in endothelial
cells and in the occasional immune cells that were present, but not
in vascular smooth muscle cells (Fig. 1A). In atherosclerotic plaque
lesions, an abundance of infiltrating macrophages and foam cells
were present that all strongly expressed PHACTR1, but no expres-
sion was seen in vascular smooth muscle cells (Fig. 1B, C). Plaque
endothelial cells also expressed PHACTR1 (Fig. 1B). Lymphocytes in
peri-plaque adventitial aggregates also expressed PHACTR1 and
this was present in both the cytoplasm and nucleus (Fig. 1D).
PHACTR1 was also expressed by lymphocytes in secondary
lymphoid tissue (tonsillar), but here it was predominantly in the
cytoplasm, rather than the nucleus (Fig. 1E). Overall, the immu-
nohistochemistry results highlight the marked expression of
PHACTR1 in immune cells in atherosclerosis, particularly in mac-
rophages and lipid-laden foam cells.3.2. PHACTR1 expresses multiple transcripts from two promoters in
vascular and immune cells
We next determined the expression pattern of PHACTR1 in pri-
mary human atherosclerosis-related cell types involved in athero-
sclerosis. A combined genomic analysis of human expressed
sequence tag (EST) data, chromatin state mapping based on ChIP-
seq data and CAP analysis of gene expression with high
throughput sequencing (CAGE-seq) [29,30] suggested the presence
of a transcriptional start site (TSS) around 240 kb downstream from
that of the reported Refseq transcript (NM_030948.2) and a further
TSS close to the 30 end of this transcript (Fig. 2A). To determine the
origin of transcripts in cell types involved in atherosclerosis, we
mapped the TSS using Rapid Amplification of cDNA Ends (RACE) in
primary human macrophages, aortic endothelial cells (HAEC),
monocytes and peripheral blood mononuclear cells (PBMC)
depleted of CD14þmonocytes (Fig. 2A, Supplementary data 1). This
demonstrated that the known TSS of the human RefSeq transcript
(NM_030948.2) was not used, but instead the RACE clones
confirmed a TSS 240 kb downstream, that was supported by the
EST, chromatin state and CAGE-seq data (Fig. 2A). We used the
RACE results to design primers to amplify and clone a 1674 bp open
reading frame from primary human macrophages and arterial
endothelial cells. This transcript encodes a 557 amino acid
PHACTR1 isoform that matches the predicted NCBI Reference
Sequence: XP_011512694.1 (Fig. 2A/B, Supplementary data 1). On
the basis of its length, we refer to this transcript as the ‘interme-
diate transcript’. The open reading frame of the intermediate
transcript begins partway through exon 3 of NM_030948.2 and
contains all subsequent downstream exons. Additionally, the in-
termediate transcript includes an extra exon (exon 6) that is not
present in NM_030948.2 (Fig. 2B/C). In CD14þ-depleted PBMCs, the
transcriptional start site was around 600 bp upstream of that seen
in both primary arterial endothelial cells and CD14þ cells, but this
did not alter the open reading frame.
The genomic analysis supported the presence of a distal TSS that
matched the beginning of ENSEMBL transcript ENST00000379335
[29,30] (Fig. 2 A/B). Additional analysis of chromatin mapping data
from our previous study of primary human macrophages demon-
strated an open chromatin site at the TSS that was flanked by
H3K27ac-marked histones consistent with promoter activity [17].
Using this information, we cloned a 435 bp transcript from mac-
rophages, which encoded a 144 amino acid protein. This ‘short’
transcript shares its last four 4 exons with the longer transcripts,
but begins with an extended version of exon 10 that starts 50 to the
exon 10 start position seen in the longer transcripts (Fig. 2B/C).3.3. PHACTR1 transcripts display tissue-specific differential
expression
We designed transcript-specific primer pairs to examine the
expression pattern of the long, intermediate and short transcripts
in atherosclerosis-related cell types (Table 1). The long transcript
was not expressed in primary human monocytes, macrophages,
HAEC, VSMC, T cells, B cells or CD14þ-depleted PBMC (Fig. 3A). The
intermediate transcript was expressed in macrophages, HAEC and
VSMC (Fig. 3A), but was barely detectable in monocytes and B cells
and absent from T cells. The short transcript was expressed in
primary human monocytes, macrophages, B cells, CD14þ-depleted
PBMC, and to a lesser extent in T cells, but was absent from HAEC
and VSMC (Fig. 3A).
We screened a panel of adult and fetal tissues and the long
transcript was only present in adult brain tissue (Fig. 3B). The in-
termediate transcript was expressed in pancreas and fetal heart
(Fig. 3B). The short transcript was expressed in adult spleen, fetal
spleen, PBMC, colon and at a low level in the thymus (Fig. 3B).
Overall, the long transcript is restricted to neuronal tissue only and
the intermediate transcript is more variable, being present in HAEC,
VSMC and macrophages. The short transcript is restricted to im-
mune cells.
3.4. PHACTR1 protein is expressed in macrophages and HAEC but
not VSMC
To assess PHACTR1 protein expression in primary human cells,
western blotting was undertaken using an antibody raised against a
region of the protein shared by all PHACTR1 isoforms. Recombinant
PHACTR1 isoforms were expressed and analyzed in parallel to
facilitate molecular size comparison (Fig. 3C). The isoform encoded
by the long transcript migrated with an apparent molecular weight
of about 75 kDa (predicted 66 kDa, pI 6.51), similar to that of the rat
brain isoform (Fig. 3C) [18]. The intermediate isoform is 23 amino
acids shorter, but migrated with an apparently higher molecular
weight, equivalent to about 80 kDa (predicted 64 kDa, pI 6.81)
(Fig. 3C). This apparently anomalous migration pattern may arise
from differences between the protein isoforms such as shape, ri-
gidity, charge or post translational modification. Notably, exon 6 is
rich in proline residues that may increase rigidity (14 of 69 residues
in exon 6 are proline). Exon 6 in the intermediate isoform does not
contain any additional predicted glycosylation motifs. PHACTR1
protein was completely absent from primary vascular smooth
muscle cells despite moderate level mRNA expression in these cells
(Fig. 3C). In primary human macrophages, foam cells, HAEC and
oxLDL-treated HAEC there was strong expression of the interme-
diate isoform (Fig. 3C). We did not detect protein expression of the
short transcript but detection of this protein was difficult even
following overexpression in 293T cells (Fig. 3C and D). Although it
was not possible to assess the endogenous short isoform reliably,
these findings are consistent with our transcript studies and indi-
cate that primary macrophages and arterial endothelial cells ex-
press the intermediate, but not the long protein isoform.
3.5. PHACTR1 expression is regulated by oxLDL and inflammatory
stimuli in macrophages and endothelial cells
Given the association of the PHACTR1 locus with CAD and its
expression in atherosclerotic lesions, we hypothesized that
PHACTR1 would be regulated by atherogenic and inflammatory
stimuli. We used transcript-specific RTqPCR to assess expression of
PHACTR1 in response to a variety of stimuli. Lipopolysaccharide
(LPS) treatment of primary human macrophages upregulated the
intermediate transcript (fold ¼ 4.68, p < 0.0001), but
Fig. 1. Immunohistochemistry demonstrates in vivo PHACTR1 expression in atherosclerotic plaque. (A) Healthy aorta demonstrates PHACTR1-positive endothelium (arrowed),
but vascular smooth muscle cells in the sub-intimal layer lack PHACTR1 staining. (B) Atherosclerotic plaque showing endothelial positivity (arrowed) and positivity in the sub-
intimal space, comprising predominantly foam cells. (C) Higher power view of foam cells in atherosclerotic plaque showing cytoplasmic and nuclear staining for PHACTR1
(Green arrows indicate examples of strongly stained foam cell nuclei. Cytoplasmic foam cell staining is present in the lighter brown areas that asymmetrically encircle the nuclei).
(D) Lymphocytic aggregate in aortic adventitia of atherosclerotic vessel showing strong positivity for PHACTR1. The PHACTR1 staining is present throughout the cells, indicating
nuclear and cytoplasmic distribution. (E) Germinal centre in tonsillar lymphoid tissue; lymphocytes lack nuclear PHACTR1 as demonstrated by a thin rim of brown cytoplasmic
staining with unstained, blue nuclei (example lymphocytes arrowed). Staining for human PHACTR1, using HRP/DAB, each section representative of data from 5 individuals per
condition, scale bars indicate 50 mm.
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p < 0.0001) (Fig. 4A). The inflammatory cytokine Tumor Necrosis
Factor-alpha (TNFa) produced a similar, but weaker effect with
upregulation of the intermediate transcript (fold ¼ 1.41, p ¼ 0.04)
and downregulation of the short transcript (fold ¼ 0.64, p ¼ 0.02)
(Fig. 4A). OxLDL exerted a converse effect on expression of
PHACTR1 compared to LPS and TNFa; the short transcript was
upregulated 6 fold (p ¼ 0.004) and the intermediate transcript was
downregulated (fold ¼ 0.74, p ¼ 0.01) (Fig. 4B). Oxidized 1-
palmitoyl-2-arachidonyl-sn- glycero-3-phosphorylcholine(oxPAPC) is a mixture of oxidized phospholipids that have a
similar biological effect to minimally oxidized LDL [31]. OxPAPC
contains components of the biologically active fractions of HPLC-
separated minimally-modified LDL [31]. In macrophages OxPAPC
produced a similar directional effect to oxLDLdupregulation of the
short transcript (fold ¼ 2.28, p ¼ 0.002) and a trend towards
downregulation of the intermediate transcript (fold ¼ 0.83,
p ¼ 0.12) (Fig. 4B). To refine the lipid species responsible for the
effect on PHACTR1 expression we loaded macrophages with
cholesterol itself. Cells were treatedwith a cyclodextrin-cholesterol
Fig. 2. The structure of human PHACTR1 transcripts. (A) The transcript structure for PHACTR1 is shown for RefSeq curated transcripts showing 2 transcripts in blue. Shown below
is human expressed sequence tag data, which is suggestive of a transcription start site halfway along the gene and a further possible site at the 30 end of the gene. These data were
compared to chromatin state data that uses multiple ChIP-seq markers to classify the genome into different types of regulatory element or transcription state. Chromatin state maps
are shown for 9 cell types with the chromatin state colored (red - promoter, orange - enhancer, yellow - weak enhancer, blue - insulator, green - transcribed, dark grey - not
transcribed). Red regions depicting active promoter elements are seen half way along the gene, coinciding with a TSS suggested by EST data. In one cell type, a promoter is also seen
at the 30 end. These sites coincide with precise TSSs identified by CAGE-seq in a variety of human cell types. Taken together, these data suggest three main TSS in three main
promoter regions. The position of coronary artery disease risk variant, rs9349379, is indicated by the red triangle. (B) The transcript structure for the RefSeq transcript is shown
uppermost and is aligned to the intermediate transcript that was cloned from macrophages and endothelial cells. The short transcript cloned from macrophages is also shown
below. Vertical lines indicate exons. (C) Coding structure of PHACTR1 transcripts with exons drawn to scale and motifs annotated. Motif locations were predicted using the
Eukaryotic Linear Motif resource. The region of experimentally proven PP1 binding is shown in green.
Table 1
Summary of expression pattern of 3 different PHACTR1 transcripts (mRNA) in pri-
mary human cell types relevant to atherosclerosis.
Long Intermediate Short
Macrophages No Yes Yes
Arterial endothelial cells No Yes No
Vascular smooth muscle cells No Yes No
PBMC depleted of CD14þ cells No Yes Yes
B cells (CD19þ) No Barely detectable Yes
T cells (CD3þ) No No Barely detectable
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vascular smooth muscle cells [32,33]. Unlike the oxidized stimuli,
cholesterol loading had no effect on PHACTR1 expression (Fig. 4B).
Overall, these data indicate that in macrophages inflammatory
pathways downregulate the short transcript and upregulate the
intermediate transcript, whereas oxidized lipid-responsive path-
ways upregulate the short transcript. In human aortic endothelial
cellsdwhich only express the intermediate transcriptdboth TNFa
and oxLDL upregulated PHACTR1 (fold ¼ 2.5, p ¼ 0.007, and
fold ¼ 1.8, p ¼ 0.009, respectively) (Fig. 4C). As with macrophages,
cholesterol loading with cyclodextrin-cholesterol had no effect on
Fig. 3. PHACTR1 expression patterns in primary cells and tissues. (A) Expression in purified primary human cells showed that the long transcript was not expressed among the
cells tested. By contrast, the intermediate transcript showed robust expression in human monocytes, macrophages, arterial endothelial cells (HAEC) and vascular smooth muscle
cells (VSMC), but was not expressed by T cells and was barely detectable in B cells and PBMC-depleted of monocytes. (B) Analysis of a human tissue cDNA panel showed the long
transcript exclusively expressed in adult brain. The intermediate transcript showed strong expression in the pancreas, but was also detectable in fetal heart. By contrast, the short
transcript was present in PBMC and spleen, including fetal spleen. (C) Western blotting: PHACTR1 over-expression in 293T cells transfected with the long and intermediate isoforms
compared to endogenous PHACTR1 in primary human cells. The shorter intermediate isoform has an apparently greater size than the long isoform in 293T cells. Macrophages, foam
cells and HAECs expressed PHACTR1 with a similar size to the intermediate isoform. PHACTR1 protein was absent from VSMC. A band corresponding to endogenous expression of
the short isoform was not seen in any cell type. The polyclonal rabbit anti-PHACTR1 antibody identifies a non-specific additional band at about 47 kDa even in untransfected cells,
which do not express PHACTR1. (D) Western blotting with over-expression in 293T cells of the short transcript cloned from macrophages. A cloned form of the intermediate
transcript skipping exons 5e9 is also shown for comparison.
M.E. Reschen et al. / Atherosclerosis 250 (2016) 95e105 101PHACTR1 expression. In vascular smooth muscle cells, cholesterol
loading had no effect on expression of the intermediate PHACTR1
transcript.
3.6. Genetic regulation of PHACTR1 expression by CAD SNP
rs9349379
The rs9349379 SNP at the PHACTR1 locus has been implicated
by GWAS in the genetic risk of CAD [11,34]. The mechanism by
which different alleles of this SNP influence CAD risk is unknown.
Rs9349379 is in an intronic region of PHACTR1 and is not in high
linkage disequilibrium with any coding SNPs; it may therefore
affect transcriptional regulation of PHACTR1. Using transcript-
specific real time quantitative PCR, we tested for an associationbetween the alleles of rs9349379 and expression of PHACTR1 in
macrophages and CD14þ-depleted PBMC. To do this we used
primary cells derived from healthy non-smoking Caucasian in-
dividuals controlled for age (>18, <50 years), body mass index,
cholesterol and triglyceride levels but with differing rs9349379
genotypes. There was a significant allelic effect on expression of
the short transcript; the A allele was associated with higher
expression (Fig. 5A). Macrophages from individuals homozygous
for the protective A allele had 2.5-fold higher expression than
macrophages from individuals homozygous for the G allele, which
is the coronary artery disease risk-associated allele (p ¼ 0.0187).
There was a trend towards reduced expression of the intermediate
transcript with the A allele, but this did not reach significance
(Fig. 5B). In CD14þ-depleted PBMCs no association was detectable
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mediate transcript (Fig. 5C, D). Overall, these results demonstrate
that rs9349379 is both a CAD risk-associated variant and an
expression quantitative trait locus (eQTL) for PHACTR1 in mac-
rophages, but not in CD14þ-depleted PBMC. Therefore, decreased
expression of the short transcript in macrophages is associated
with CAD. This genetic risk effect recapitulates the effect of LPS,
which also caused suppression of the short transcript (Fig. 5A).
Overall, these findings demonstrate that the CAD risk effect of
genetic variants at rs9349379 may be operational in macrophages
in atherosclerotic lesions.4. Discussion
GWAS of complex diseases have identified genomic loci con-
taining genetic variants that affect heritable disease risk [4]. For
CAD, one of the most robust reported risk loci is at the PHACTR1
gene locus where several studies have identified intronic SNPs that
are associated with the risk of myocardial infarction, coronary
stenosis and coronary calcification [9e11,34]. The same CAD risk
SNP allele is associated with protection from a non-atherosclerotic
form of vascular disease; cervical artery dissection. Unravelling the
biological pathways underpinning the pleiotropic effect of the
Fig. 5. Genotype of CAD risk SNP rs9349379 affects expression of the short PHACTR1 transcript in macrophages. PHACTR1 expression in primary human macrophages relative
to GAPDH. (A) A significant genotype-expression level correlation was demonstrated in primary human macrophages (n ¼ 19, AA ¼ 6, AG ¼ 8, GG ¼ 5). Individuals with the AA
genotype had the highest level of expression of the short PHACTR1 transcript and subjects with the GG genotype had the lowest expression. (B) There was no significant correlation
with the intermediate transcript (n ¼ 19). (C, D) Primary human CD14þ-depleted PBMCs did not show a significant correlation between expression and genotype of rs9349379
(n ¼ 20, AA ¼ 7, AG ¼ 8, GG ¼ 5).
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yielded by GWAS studies [14]. To better understand the role of
PHACTR1 in atherosclerosis, we investigated PHACTR1 expression
and the regulatory influence of inflammatory stimuli, atherogenic
lipid and genetic variation.
Using immunohistochemistry, we demonstrated increased
expression of PHACTR1 in atherosclerotic lesions in vivo. Lipid-
laden macrophages or foam cells were clearly the most abundant
source of PHACTR1 in plaques. The distribution was both nuclear
and cytoplasmic in macrophages, foam cells and adventitial lym-
phocytes, whereas in secondary lymphoid tissue lymphocytes,
PHACTR1 was excluded from the nucleus. This differential intra-
cellular localization may reflect the accumulation in atherosclerotic
plaques of inflammatory lipids including lysophosphatidic acid
(LPA), which activates RhoA signaling causing G- to F-actin poly-
merization, a mechanism known to promote PHACTR1 nuclearaccumulation [35].
The previously reported PHACTR1 transcript was isolated from
brain and encodes a 580 amino acid protein [18,19]. We only found
expression of this long PHACTR1 transcript in brain. Previous mo-
lecular and functional studies have focused on this transcript,
which may limit their relevance to understanding the role of
PHACTR1 beyond the nervous system. In cell types involved in
atherosclerotic lesions, we found that PHACTR1 was transcribed
from a more distal TSS giving rise to the intermediate transcript.
This intermediate transcript was the prevalent protein isoform in
immune and endothelial cells and the encoded protein includes the
4 previously characterized actin-binding RPEL domains and NLS
regions. In addition, we found transcription of a short transcript
from an even more distal TSS. The encoded protein would only
contain two RPEL motifs and lack the N-terminal NLS. The
expression pattern of the short transcript differed markedly from
M.E. Reschen et al. / Atherosclerosis 250 (2016) 95e105104the longer forms and expressionwas only detected in immune cells,
principally macrophages and B-lymphocytes. Macrophages were
notable as the only cell type with high-level expression of the in-
termediate and short transcript. The limited distribution in im-
mune cells is consistent with a role for the short transcript in
immunity and inflammation. We were unable to detect protein
expressed from the endogenous short transcript in the cell types
studied despite using an antibody raised against peptides encom-
passing most of its coding region. This may indicate post-
transcriptional effects, rapid turnover or technical limitations of
the available antibodies. A striking finding was the absence of
PHACTR1 protein in VSMC.
In macrophages, oxLDL exposure caused upregulation of the
short transcript and suppression of the intermediate transcript
whereas lipopolysaccharide and TNFa caused upregulation of the
intermediate transcript and suppression of the short transcript.
These findings demonstrate that PHACTR1 expression responds
differently to inflammatory stimuli and to lipid or oxidative stress
pathways activated by oxLDL. The effect of the lipid stimulus was
not dependent on the presence of lipoproteins since synthetic
oxidized phospholipids (oxPAPC) produced a similar response to
oxLDL. A non-oxidized, non-lipoprotein stimulus, comprising pure
cholesterol loading did not affect expression of PHACTR1 suggest-
ing that oxidized lipids are required.
In endothelial cells only the intermediate transcript was
expressed and this was upregulated by oxLDL but not by non-
oxidized, non-lipoprotein cholesterol loading. In previous studies
with umbilical vein endothelial cells TNFa had no effect on
PHACTR1 expression [15,23]. However, we found that PHACTR1
was upregulated by TNFa in primary aortic arterial endothelial
cells, indicating the difference between adult arterial endothelial
cells and neonatal umbilical cord vein endothelial cells. These
findings raise the possibility that oxLDL and TNFa could influence
angiogenesis or atherosclerosis by affecting PHACTR1 expression in
arterial endothelial cells. A previous study in HUVECs reported
upregulation of PHACTR1 in response to the classic angiogenic
factor, vascular endothelial growth factor [36].
The rs9349379 SNP is robustly associated with CAD and a fine
mapping study suggested it was the likely causal variant in the
region [15]. Previous eQTL studies have not taken account of the
different PHACTR1 transcripts and so have not been informative
about each transcript. A large-scale eQTL study in monocytes used
microarray technology with a probe that would have detected
multiple PHACTR1 transcripts [37]. An eQTL study of CAD candidate
genes, did not detect significant PHACTR1 expression in PBMC, but
the Taqman assay usedwould only assess the long transcript, which
is not expressed in these cells [38]. An eQTL for PHACTR1 expression
has recently been demonstrated in right coronary artery tissue, but
the cellular origin of this effect was unclear due to the mixed cell
populations in the tissue samples [15]. In addition, the different
transcripts were not distinguished because the qPCR primers
annealed to both the long and intermediate transcripts and the
short transcript was not studied [15]. Using RNA-seq eQTLs were
sought across a panel of human tissues and the rs9349379 SNP was
found to be an eQTL for PHACTR1 in coronary artery, tibial artery
and aortic artery tissue; the reference allele A was associated with
higher PHACTR1 expression than the alternative G allele [16]. In
this study, the composite nature of the tissue samples does not
allow identification of the cellular origin of the effect and the
transcript affected was not reported. The direction of genetic effect
is the same as that of the short transcript in the present study. An
eQTL study in endothelial cells using primers that would detect
only the longer transcripts did not find a significant association
with variants at the rs12526453 SNP, which is in linkage disequi-
librium with rs9349379 (R2 with rs9349379 ¼ 0.32) [39]. We havenow established a new association in macrophages between
expression of the previously uncharacterized short PHACTR1 tran-
script and genotype at rs9349379. In PBMCs-depleted of CD14þ
cells (predominantly lymphocytes) there was a trend towards an
eQTL effect in the opposite direction to that in macrophages. A
previous study found that 4.4% of eQTL-associated SNPs produced
opposite effects in different tissues [40].
Suppression of the short PHACTR1 transcript in macrophages by
pro-inflammatory stimuli mirrors the effect of the CAD risk allele
(rs9349379-G), which is associated with reduced expression of the
short transcript compared to that seen with the protective allele
(rs9349379-A). This suggests that having the risk genotype is, in
this sense, equivalent to a persistent inflammatory stimulus, such
as that caused by LPS. As the short transcript was only expressed in
immune cells, these data imply that the short transcript could play
a role in the macrophage inflammatory response in atherosclerotic
plaques.
The rs9349379 SNP is located about 250 kb upstream from the
short PHACTR1 transcript. At other risk loci chromatin looping has
been established as a mechanism whereby regulatory elements
containing the SNP are brought into proximity with the genewhose
expression is altered. The DEXI gene, for example, is physically
linked by chromatin looping to a type 1 diabetes risk SNP about
150 kb away and the SNP has an eQTL for DEXI [41]. We and others
have found that GWAS risk SNPs alleles affect enhancer function by
altering transcription factor binding affinity at regulatory elements
[6,17]. We hypothesize that such a mechanism may be responsible
for the effect of rs9349379 and the G allele is predicted to reduce
binding of MEF2 transcription factors, that are expressed in mac-
rophages [17,42e44].
Determining themechanisms underlying the CAD risk conferred
by GWAS-identified genetic risk variants is a major challenge for
atherosclerosis research, especially for loci containing poorly
characterized genes. We establish PHACTR1 as an important gene
expressed in atherosclerotic lesions and as the candidate gene at
the PHACTR1 CAD locus by demonstrating genetic regulation of a
novel transcript and regulation by atherogenic stimuli. Previous
molecular studies of PHACTR1 focused on a transcript which we
show is not expressed in cells involved in atherosclerotic lesions.
We have identified novel intermediate and short length transcripts
as the dominant forms expressed in cells involved in atheroscle-
rosis. Our genotype-expression analysis shows that the CAD-
associated genetic variant is active in macrophages, the dominant
cell type expressing PHACTR1 in human atherosclerotic plaques.
The effects of the CAD risk genotype mirror those of an inflam-
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